Psyllium and Proposition 65 Warnings
The provided medical evidence does not address whether psyllium products carry California Proposition 65 warnings, as this is a regulatory labeling question rather than a clinical efficacy or safety issue.
What the Evidence Actually Covers
The evidence provided focuses entirely on:
- Clinical efficacy: Psyllium's effectiveness for chronic constipation 1, 2
- Safety concerns: FDA regulation of granular psyllium formulations due to esophageal obstruction risk 3
- Health benefits: Metabolic effects and functional food applications 4, 5, 6
- General Proposition 65 impacts: How the law affects product reformulation across industries 7, but without specific mention of psyllium
Understanding Proposition 65
California's Proposition 65 requires warnings on products containing chemicals known to cause cancer, birth defects, or reproductive harm 7. The law has prompted widespread product reformulation across industries, with businesses changing ingredients to avoid warning labels 7.
The Clinical Safety Profile
From a medical safety standpoint:
- FDA has banned granular psyllium formulations due to esophageal obstruction risk, but allows powders, tablets, and wafers 3
- Clinical guidelines recommend psyllium as an effective first-line fiber supplement for constipation 1, 2
- Common side effects include flatulence, with adequate hydration recommended 1
The Gap in Evidence
None of the provided medical literature addresses Proposition 65 labeling requirements for psyllium products. This is a regulatory compliance question that would require:
- Review of California's official Proposition 65 chemical list
- Examination of specific psyllium product labels
- Consultation of manufacturer compliance documentation
For clinical practice purposes, psyllium remains a recommended, evidence-based treatment for constipation with well-characterized safety concerns unrelated to Proposition 65 chemicals 1, 2.